News & Blog

NBTS Brain Tumor Clinical Trials Report: Q3 2018

New brain tumor clinical trials open around the country all the time, and it can be hard for patients and care-partners to keep track of new opportunities to consider participation in leading-edge clinical research. This report, generated by the National Brain Tumor Society, provides a summary of clinical trials that have started or begun recruitment since our last quarterly report. This report can be used to identify new trials that are enrolling volunteers and make informed decisions about how clinical research might fit into your treatment plans. To learn more about each trial, and contact the party responsible for enrolling patients, just follow the link provided under the brief description of each listing.

For a more comprehensive list of ALL open brain tumor clinical trials, please visit the NBTS Clinical Trial Finder at, where you can search potential opportunities for enrollment based on criteria important and specific to you.

  • Evaluation of Preoperative Functional Magnetic Resonance Imaging in Patients With Brain Tumors
    • Brief Description: The purpose of this study is to test the accuracy of using an imaging technique called “breath-holding functional magnetic resonance imaging (BH fMRI)” in addition to standard imaging tools and techniques. This study will allow researchers to find out whether using BH fMRI in combination with standard tools and techniques is the same as, better, or worse than the standard approach alone in producing accurate images of brain tumors.
    • LINK:
  • Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Grade II-IV Brain Tumors
    • Brief Description: This trial studies how well a technique known as “navigated repetitive transcranial magnetic stimulation” works in improving motor rehabilitation in participants with grade II-IV brain tumors. Navigated repetitive transcranial magnetic stimulation may help improve patients’ lost motor function after surgery.
    • LINK: 
  • Surgical Tissue Flap to Bypass the Blood-Brain-Barrier in GBM Patients
    • Brief Description: This study assesses the safety of using tissue autograft of a pericranial flap into the resection cavity of newly diagnosed glioblastoma patients. The objective of the study is to demonstrate that this surgical technique is safe in a small group of patients with resected newly diagnosed GBM and may improve progression-free survival (PFS).
    • LINK:
  • Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (CSCRGBM)
    • Brief Description: A phase III clinical trial to determine if recurrent glioblastoma patients treated with drugs predicted by the ChemoID test will have better outcomes than patients treated with standard-of-care control therapy chosen by the treating doctor.
    • LINK:
  • HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
    • Brief Description: This phase I-II study will assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for newly diagnosed anaplastic astrocytoma and glioblastoma patients.
    • LINK:
  • HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
    • Brief Description: This phase I-II trial is similar and related to the previously listed trial above, except it is designed for recurrent (as opposed to newly diagnosed) anaplastic astrocytoma and glioblastoma patients, and utilizes a different type of radiation technique.
    • LINK:
  • Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
    • Brief Description: A phase I study of the safety of the combination of ibrutinib and radiation at various dose levels in unmethylated o6-methylguanine-DNA-methyltransferase (MGMT) glioblastoma patients, as well as to study the combination of ibrutinib, temozolomide, and radiation combination therapy in methylated MGMT glioblastoma patients.
    • LINK:
  • A Phase 1b Study of PTC596 in Children With Newly Diagnosed DIPGand High-Grade Glioma
    • Brief Description: A phase I clinical trial to learn more about the safety of the study drug, PTC596, has when taken during radiation. The researchers also want to learn about the effects, if any, these drugs have on children and young adults with brain tumors.
    • LINK:
  • A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
    • Brief Description: This phase II trial will evaluate the activity of the drug panobinostat in combination with the drug everolimus for children with gliomas harboring H3.1 or H3.3K27M mutations, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (group A) and recurrent/progressive glioma (grade II-IV, including DIPG) (group B).
    • LINK:
  • ABI-009 (Nab-Rapamycin) in Recurrent High-Grade Glioma and Newly Diagnosed Glioblastoma
    • Brief Description: A phase II study of ABI-009 (nab-Rapamycin) in patients with progressive high-grade glioma following prior treatment (excluding Avastin) and patients with newly diagnosed glioblastoma. ABI-009 will be tested as a single-agent or in combination with standard therapies.
    • LINK:
  • Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
    • Brief Description: This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade III-IV glioma that has come back or does not respond to treatment.
    • LINK:
  • EDO-S101 for MGMT Unmethylated Glioblastoma
    • Brief Description: A phase I trial to find the highest tolerable dose of EDO-S101 that can be given with, or after, radiation therapy to patients with glioblastoma. The safety of this study drug will also be studied.
    • LINK:
  • Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
    • Brief Description: This phase I study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain, establish the maximum tolerated dose for infusions of 5-AZA into the fourth ventricle in patients with recurrent ependymoma, and assess the potential antitumor activity of 5-AZA.
    • LINK:
  • OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
    • Brief Description: A phase I pilot study exploring the potential benefit of adding the drug OKN-007 with temozolomide for treatment in patients with glioblastoma undergoing adjuvant concomitant radiotherapy.
    • LINK:
  • Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Cancer Patients
    • Brief Description: A phase II trial to see if gene transfer therapy shrinks tumors in certain cancer patients, including those with glioblastoma.
    • LINK:
  • Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma
    • Brief Description: A phase I study to evaluate the safety and tolerability of a single intratumoral injection of the experimental treatment, Ad-RTS-hIL-12, given with oral veledimex.
    • LINK:
  • A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma
    • Brief Description: This phase I trial is similar and related to the previously listed trial above, expect it will evaluate this treatment combination with an additional immunotherapy called nivolumab.
    • LINK:
  • Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Certain Cancers
    • Brief Description: Patients with recurrent glioblastoma that have received standard surgery, radiation therapy, and chemotherapy for their primary tumors and require resection of their tumors for palliative or other clinical indications, are eligible to participate in this phase II clinical trial studying if Tumor Infiltrating Lymphocytes (TILs) can be used to shrink tumors and are safe.
    • LINK: 
  • A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin
    • Brief Description: A phase IIIb trial to study potential treatment strategies for managing ocular side-effects in patients with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who are being treated with depatuxizumab mafodotin (ABT-414).
    • LINK:

For a downloadable PDF of this report, click here

Post a Comment

Your email is kept private. Required fields are marked *